PT2231628E - Inibidores de citocromo p450 - Google Patents

Inibidores de citocromo p450 Download PDF

Info

Publication number
PT2231628E
PT2231628E PT88694260T PT08869426T PT2231628E PT 2231628 E PT2231628 E PT 2231628E PT 88694260 T PT88694260 T PT 88694260T PT 08869426 T PT08869426 T PT 08869426T PT 2231628 E PT2231628 E PT 2231628E
Authority
PT
Portugal
Prior art keywords
formula
compounds
another embodiment
substituted
alkyl
Prior art date
Application number
PT88694260T
Other languages
English (en)
Portuguese (pt)
Inventor
Manoj Desai
Hon Chung Hui
Hongtao Liu
Lianhong Xu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PT2231628E publication Critical patent/PT2231628E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
PT88694260T 2008-01-04 2008-12-19 Inibidores de citocromo p450 PT2231628E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1907908P 2008-01-04 2008-01-04

Publications (1)

Publication Number Publication Date
PT2231628E true PT2231628E (pt) 2015-12-29

Family

ID=40380546

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88694260T PT2231628E (pt) 2008-01-04 2008-12-19 Inibidores de citocromo p450

Country Status (8)

Country Link
US (1) US8759379B2 (https=)
EP (1) EP2231628B1 (https=)
JP (2) JP5629585B2 (https=)
AU (1) AU2008346823B2 (https=)
CA (1) CA2710679A1 (https=)
ES (1) ES2555209T3 (https=)
PT (1) PT2231628E (https=)
WO (1) WO2009088719A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
WO2012088156A1 (en) * 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
CA2860995A1 (en) * 2012-01-12 2013-07-18 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
WO2014000178A1 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014105777A1 (en) * 2012-12-26 2014-07-03 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
US20160339008A1 (en) * 2013-10-25 2016-11-24 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN104628771B (zh) * 2014-08-14 2016-05-11 赫斯(西安)生物科技有限公司 抗病毒药物及其药物组合物
CN105669749B (zh) * 2014-08-14 2018-03-30 赫斯(西安)生物科技有限公司 抗病毒药物及组合物
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ N4-ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
NL2024544B1 (en) * 2018-12-21 2021-03-15 Aim Immunotech Inc Compositions And Methods For Cancer Therapy
WO2022061309A1 (en) * 2020-09-21 2022-03-24 Aim Immunotech Inc. Compositions and methods for treating cancer
US20240124431A1 (en) * 2020-12-01 2024-04-18 Orion Corporation 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5362912A (en) * 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2123065T3 (es) * 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
CA2170020C (en) 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
JP3453741B2 (ja) * 1993-07-08 2003-10-06 日本製紙株式会社 感熱記録体
US5628072A (en) * 1994-06-20 1997-05-13 Sharp Plastics Manufacturing Ltd. Eye goggles with laterally adjustable eyepieces within goggles frame
DE4424828A1 (de) * 1994-07-14 1996-01-18 Thomae Gmbh Dr K Neue substituierte Arylsulfonamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) * 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
DE19653427A1 (de) * 1996-12-20 1998-07-02 Siemens Ag Kraftsensor
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
TR200103488T2 (tr) 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.
PL204924B1 (pl) 1999-10-06 2010-02-26 Tibotec Pharm Ltd Heksahydrofuro [2,3-b] furanylo-3-N-{3(1,3-benzodioksolilo-5-sulfonylo) (izobutylo) amino] -1-benzylo-2-hydroksypropylo} karbaminian oraz jego zastosowanie
WO2001082919A2 (en) * 2000-05-04 2001-11-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
PE20060621A1 (es) * 2004-09-07 2006-06-29 Smithkline Beecham Corp 1,3-diaminas aciclicas como agonistas de los receptores del canal trpv4
US7786153B2 (en) 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
AR053845A1 (es) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
PL2049506T5 (pl) * 2006-07-07 2024-09-09 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości leków
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
ES2438275T3 (es) * 2007-07-06 2014-01-16 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de agentes terapéuticos

Also Published As

Publication number Publication date
WO2009088719A1 (en) 2009-07-16
AU2008346823B2 (en) 2015-03-12
JP2011508778A (ja) 2011-03-17
CA2710679A1 (en) 2009-07-16
JP5629585B2 (ja) 2014-11-19
AU2008346823A1 (en) 2009-07-16
EP2231628B1 (en) 2015-10-28
ES2555209T3 (es) 2015-12-29
US20090175820A1 (en) 2009-07-09
US8759379B2 (en) 2014-06-24
JP2014169338A (ja) 2014-09-18
EP2231628A1 (en) 2010-09-29
HK1148520A1 (zh) 2011-09-09

Similar Documents

Publication Publication Date Title
EP2231628B1 (en) Inhibitors of cytochrome p450
ES2546378T3 (es) Moduladores de propiedades farmacocinéticas de agentes terapéuticos
CA2678907C (en) Modulators of pharmacokinetic properties of therapeutics
AU2015204378B2 (en) Modulators of pharmacokinetic properties of therapeutics
EP2487168A1 (en) Modulators of pharmacokinetic properties of therapeutics
HK1148520B (en) Inhibitors of cytochrome p450
HK1174903A (en) Modulators of pharmacokinetic properties of therapeutics
HK1174906A (en) Modulators of pharmacokinetic properties of therapeutics
HK40034020A (en) Modulators of pharmacokinetic properties of therapeutics
HK40031994A (en) Modulators of pharmacokinetic properties of therapeutics
HK1235768A (en) Modulators of pharmacokinetic properties of therapeutics
HK1235768A1 (en) Modulators of pharmacokinetic properties of therapeutics
HK1174901A (en) Modulators of pharmacokinetic properties of therapeutics
HK1174905A (en) Modulators of pharmacokinetic properties of therapeutics
HK40112820A (en) Modulators of pharmacokinetic properties of therapeutics
NO20210811A1 (no) Modulatorer av farmakokinetikkegenskaper til terapeutika
HK1174904A (en) Modulators of pharmacokinetic properties of therapeutics
HK1174902A (en) Modulators of pharmacokinetic properties of therapeutics